IMS Capital Management Sells 800 Shares of iShares Biotechnology ETF (NASDAQ:IBB)

IMS Capital Management reduced its stake in shares of iShares Biotechnology ETF (NASDAQ:IBB) by 31.8% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,712 shares of the financial services provider’s stock after selling 800 shares during the period. IMS Capital Management’s holdings in iShares Biotechnology ETF were worth $252,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. B. Riley Wealth Advisors Inc. lifted its holdings in iShares Biotechnology ETF by 2.0% in the 2nd quarter. B. Riley Wealth Advisors Inc. now owns 11,722 shares of the financial services provider’s stock worth $1,609,000 after purchasing an additional 229 shares during the last quarter. NewEdge Advisors LLC lifted its stake in shares of iShares Biotechnology ETF by 20.1% in the second quarter. NewEdge Advisors LLC now owns 11,633 shares of the financial services provider’s stock worth $1,597,000 after buying an additional 1,944 shares during the last quarter. Creative Planning boosted its holdings in shares of iShares Biotechnology ETF by 2.9% during the 2nd quarter. Creative Planning now owns 67,902 shares of the financial services provider’s stock worth $9,320,000 after buying an additional 1,905 shares during the period. Main Management ETF Advisors LLC grew its stake in iShares Biotechnology ETF by 2.6% in the 2nd quarter. Main Management ETF Advisors LLC now owns 578,835 shares of the financial services provider’s stock valued at $79,451,000 after buying an additional 14,535 shares during the last quarter. Finally, Security National Bank of SO Dak raised its holdings in iShares Biotechnology ETF by 0.7% in the 2nd quarter. Security National Bank of SO Dak now owns 10,461 shares of the financial services provider’s stock worth $1,436,000 after acquiring an additional 75 shares during the period. Institutional investors and hedge funds own 62.45% of the company’s stock.

iShares Biotechnology ETF Stock Performance

Shares of iShares Biotechnology ETF stock opened at $145.60 on Tuesday. iShares Biotechnology ETF has a 1 year low of $111.83 and a 1 year high of $150.57. The company’s fifty day simple moving average is $145.69 and its 200-day simple moving average is $138.91.

iShares Biotechnology ETF Dividend Announcement

The company also recently announced a dividend, which was paid on Monday, September 30th. Investors of record on Wednesday, September 25th were given a dividend of $0.2005 per share. The ex-dividend date of this dividend was Wednesday, September 25th.

iShares Biotechnology ETF Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.